Close of Accelerated Bookbuild

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, is pleased to announce that, further to the announcement made at 5.00pm on 8 October 2026 (the “Launch Announcement”), the Placing has now closed and the Bookbuild has been successfully concluded.

Participants in the Placing will be contacted by Singer Capital Markets and Oberon Capital as soon as practicable later today to confirm their allocations once finalised. A further announcement will be made by the Company in due course confirming the results of the Placing. As set out in the Launch Announcement, the launch of the WRAP Retail Offer will be announced separately thereafter.

Capitalised terms used in this announcement (this “Announcement”) shall, unless defined in this announcement or unless the context provides otherwise, bear the same meaning ascribed to such terms in the Launch Announcement.

Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines transcriptomic analysis with proprietary tests with underlying technology based upon artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence.

Operating at the intersection of laboratory and data science, Verici Dx develops complex models that the Company believes answer the clinical questions that matter most with clarity and precision. All commercially available tests are built to rigorous scientific standards, validated across inclusive, and real-world patient populations to ensure clinical relevance and reliability. Verici Dx’s lead product, Tutivia™, is a post-kidney transplant test focused on early detection of acute rejection.

Information to Distributors

UK Product Governance Requirements

EU Product Governance Requirements